CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Spectrum Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Spectrum Pharmaceuticals, Inc.
Pilot House - Lewis Wharf
2 Atlantic Avenue, 6th Floor
Phone: (617) 586-3900p:617 586-3900 Boston, MA  02110  United States
This company was Merged or Acquired on 7/31/2023.
This company ceased filing statements with the SEC on 11/22/2022.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Spectrum Pharmaceuticals, Inc. is a commercial stage biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing targeted oncology therapies. The Company's product portfolio consists of one commercial product and product candidates for the treatment of cancer patients. Its commercial product candidate includes ROLVEDON (eflapegrastim), which is a long-acting granulocyte colony-stimulating factor (G-CSF) that employs a proprietary LAPSCOVERY technology designed to enhance the duration of therapeutic effects and reduce the frequency of administration. ROLVEDON is FDA-approved for the treatment of adult patients with chemotherapy-induced neutropenia. Its development pipeline includes Poziotinib is a novel, pan-HER inhibitor that is designed to irreversibly block signaling through the Epidermal Growth Factor Receptor (EGFR) family of TKIs, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202312/31/2022YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board William L.Ashton 72 6/19/2019 2/23/2018
President, Chief Executive Officer, Director Thomas J.Riga 47 5/25/2022 12/17/2017
Chief Financial Officer, Executive Vice President Nora E.Brennan 54 5/25/2022 12/10/2020
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Allos Therapeutics, Inc.
NTR
Spectrum Oncology Private Limited
5 additional Business Names available in full report.

General Information
Number of Employees: 86 (As of 12/31/2022)
Outstanding Shares: 205,245,727 (As of 6/13/2023)
Shareholders: 157
Stock Exchange: NASD
Federal Tax Id: 930979187


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 26, 2024